LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

BÚTOVÁ Romana VYCHYTILOVÁ Petra GREGOROVÁ Jana RADOVÁ Lenka ALMASI Martina BEZDEKOVA Renata BROŽOVÁ Lucie JARKOVSKÝ Jiří KNECHTOVA Zdenka ŠTORK Martin POUR Luděk ŠEVČÍKOVÁ Sabina

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj Biomedicines
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.mdpi.com/2227-9059/9/11/1637
Doi http://dx.doi.org/10.3390/biomedicines9111637
Klíčová slova multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression
Popis Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.